Overview
Primary immunodeficiency with post-measles-mumps-rubella (MMR) vaccine viral infection is a very rare and serious condition. It happens when a person who has an underlying immune system deficiency receives the MMR vaccine — which contains live, weakened viruses — and their immune system cannot control those vaccine viruses. Instead of being harmless, the weakened measles, mumps, or rubella viruses in the vaccine can spread through the body and cause real disease. This is sometimes called 'vaccine-strain viral disease' or 'post-vaccine viral infection in immunodeficiency.' The immune system normally acts like a security guard, stopping viruses from spreading. In people with primary immunodeficiency (PID), this security system has a defect — often present from birth — that makes it unable to fight off even weakened vaccine viruses. The result can be serious infections affecting the brain, lungs, liver, and other organs. Symptoms can appear weeks to months after vaccination and may include brain inflammation, pneumonia, and widespread organ involvement. Treatment focuses on managing the active viral infection, supporting the immune system, and treating the underlying immunodeficiency. Intravenous immunoglobulin (IVIG), antiviral medications, and in some cases hematopoietic stem cell transplant (bone marrow transplant) may be used. Early identification of the underlying immune defect is critical to preventing this complication in the first place.
Key symptoms:
Brain inflammation (encephalitis) causing confusion, seizures, or personality changesPersistent fever that does not go awayLung infection or pneumonia causing breathing difficultiesSkin rash similar to measlesSwollen lymph nodesLiver inflammation causing yellowing of the skin or eyes (jaundice)Severe and repeated infectionsFailure to thrive or poor weight gain in infantsMuscle weakness or loss of coordinationHeadaches and sensitivity to lightDiarrhea and stomach pain
Variable
Can be inherited in different ways depending on the underlying gene
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection.
Community
No community posts yet. Be the first to share your experience with Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection.
Start the conversation →Latest news about Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection
No recent news articles for Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What type of primary immunodeficiency does my child have, and which gene is affected?,Is my child at risk for complications from any other live vaccines?,What antiviral treatments are available, and what is the evidence for them?,Is my child a candidate for a bone marrow transplant or gene therapy?,Should other family members be tested for the same immune deficiency?,What long-term monitoring does my child need for neurological or other complications?,Are there clinical trials or research studies we should consider?
Common questions about Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection
What is Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection?
Primary immunodeficiency with post-measles-mumps-rubella (MMR) vaccine viral infection is a very rare and serious condition. It happens when a person who has an underlying immune system deficiency receives the MMR vaccine — which contains live, weakened viruses — and their immune system cannot control those vaccine viruses. Instead of being harmless, the weakened measles, mumps, or rubella viruses in the vaccine can spread through the body and cause real disease. This is sometimes called 'vaccine-strain viral disease' or 'post-vaccine viral infection in immunodeficiency.' The immune system no
At what age does Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection typically begin?
Typical onset of Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection is infantile. Age of onset can vary across affected individuals.